Fluralaner chewable tablet and a method for preparing the same

Abstract

The application belongs to the technical field of veterinary drugs, and specifically discloses a fluclorolide chewable tablet and a preparation method thereof. The fluclorolide chewable tablet comprises the following components in percentage by mass: 14-18% fluclorolide compound, 6-10% feeding agent, 6-10% flavoring agent, 6-10% binder, 10-15% wetting agent, 3-6% disintegrating agent, 2-5% lubricant, and the rest is a filler. The fluclorolide chewable tablet disclosed in the application takes the filler and the fluclorolide compound as the base materials, and the feeding agent, the flavoring agent, the binder, the wetting agent, the disintegrating agent and the lubricant are added. The fluclorolide chewable tablet prepared by reasonably screening the types of the auxiliary materials and controlling the proportion has good stability, excellent in-vitro dissolution performance, can significantly improve the in-vivo release effect of the drug, and effectively improves the in-vivo bioavailability of fluclorolide.

Description

Technical Field

[0001] This invention relates to the field of veterinary drug technology, specifically to a flurana chewable tablet and its preparation method. Background Technology

[0002] Fluranal is a broad-spectrum isoxazoline insecticide and anthelmintic with a unique pharmacological mechanism of action. It works by specifically blocking γ-aminobutyric acid receptors and glutamate-gated chloride channels in arthropods, interfering with the nervous system transmission of parasites and external pests, thus achieving highly effective control of external and internal parasites in companion animals such as dogs and cats. This drug boasts advantages such as a broad insecticidal spectrum, long-lasting anthelmintic effect, low toxicity, and low resistance, making it widely used in pet parasite control. Compared to traditional anthelmintics such as avermectin and fipronil, fluranal has significant technical advantages in long-lasting anthelmintic effects and stability in combination with other insecticides, indicating a promising market prospect.

[0003] Currently, most commercially available fluranal formulations are in the form of ordinary oral tablets and topical drops, which present numerous technical shortcomings and usage challenges in actual veterinary clinical applications. Topical drops, in particular, are cumbersome to administer, easily affected by pet bathing, rain, and friction from fur, leading to drug loss and reduced efficacy. Furthermore, topical preparations are prone to causing adverse reactions such as skin allergies and itching in pets, and have low bioavailability. Conventional fluranal oral tablets are mostly ordinary compressed tablets with simple formulations, resulting in poor drug stability and slow dissolution rates. During storage, they are susceptible to environmental factors such as temperature, humidity, and light, leading to drug degradation, decreased active ingredient content, tablet cracking, and powdering, significantly shortening the product's shelf life.

[0004] Therefore, this application is submitted. Summary of the Invention

[0005] This invention provides a flurana chewable tablet and a method for preparing the same. The flurana described in this application has excellent stability, dissolution rate and bioavailability.

[0006] The present invention solves its technical problem by adopting the following technical solution: A flurana chewable tablet comprises the following components by weight percentage: 19-23% flurana complex, 6-10% palatability enhancer, 6-10% flavoring agent, 6-10% binder, 10-15% wetting agent, 3-6% disintegrant, 2-5% lubricant, and the balance being filler.

[0007] As an embodiment of this application, the preparation method of the freranil complex is as follows: (1) Disperse fluorenazine in anhydrous ethanol to obtain fluorenazine solution; disperse sodium caseinate in water to obtain sodium caseinate solution; (2) Add sodium caseinate solution to freranilate solution, adjust pH to 8.8~9.2, stir for 20~40 min, then adjust pH to 7.5~7.8, stir for 30~50 min, then add vitamin E polyethylene glycol succinate and betaine, stir evenly to obtain a mixture; (3) The mixture was subjected to high-pressure microjet treatment, freeze-dried, and ground to obtain the Freranar complex.

[0008] As an embodiment of this application, the mass ratio of the fluranar to anhydrous ethanol is 1:(5~20).

[0009] As an embodiment of this application, the mass ratio of sodium caseinate to water is 1:(5~20).

[0010] As an embodiment of this application, the mass ratio of sodium caseinate solution, freranilate solution, vitamin E polyethylene glycol succinate, and betaine is (0.4~0.6):1, (0.01~0.02):(0.01~0.02).

[0011] As an embodiment of this application, the pressure of the high-pressure microjet is 10,000 to 20,000 psi, and the treatment is performed 2 to 3 times.

[0012] As an embodiment of this application, the filler is prepared by dispersing microcrystalline cellulose in water, adding pectin monoglyceride and octyl glucoside, stirring evenly to obtain a modified solution; adding calcium hydroxyphosphate and corn starch to the modified solution, stirring at 35~45°C for 20~60 min, freeze-drying, grinding to obtain the filler.

[0013] As an implementation scheme of this application, the mass ratio of microcrystalline cellulose, water, pectin monoglyceride, octyl glucoside, hydroxyapatite, and corn starch is (0.12~0.15):(5~20):(0.08~0.12):(0.05~0.08):(0.25~0.3):1.

[0014] As an embodiment of this application, the palatability enhancer is at least one of chicken powder and pork liver powder.

[0015] As an embodiment of this application, the flavoring agent is at least one of sucrose, sorbitol, maltitol, isomaltitol, and sucralose.

[0016] As an embodiment of this application, the adhesive is polyethylene glycol 3350.

[0017] As an embodiment of this application, the wetting agent is at least one of soybean oil and glycerin.

[0018] As an embodiment of this application, the disintegrant is at least one of low-substituted hydroxypropyl cellulose and sodium carboxymethyl starch.

[0019] As an embodiment of this application, the lubricant is magnesium stearate.

[0020] This application also provides a method for preparing flurana chewable tablets, comprising the following steps: mixing flurana complex, palatability enhancer, flavoring agent, disintegrant, lubricant, and filler evenly, then adding binder and wetting agent, mixing evenly, and compressing into tablets to obtain flurana chewable tablets.

[0021] The beneficial effects of the present invention are as follows: The flurana chewable tablets described in this application are based on fillers and flurana complexes. By adding palatability enhancers, flavoring agents, binders, wetting agents, disintegrants and lubricants, and by rationally screening the types of excipients and controlling their proportions, the resulting flurana chewable tablets have good stability and excellent in vitro dissolution performance, which can significantly improve the in vivo release effect of the drug and effectively improve the in vivo bioavailability of flurana. Detailed Implementation

[0022] To make the objectives, technical solutions, and advantages of the embodiments of the present invention clearer, the technical solutions in the embodiments of the present invention will be clearly and completely described below. Obviously, the described embodiments are only some embodiments of the present invention, not all embodiments. Based on the embodiments of the present invention, all other embodiments obtained by those skilled in the art without creative effort are within the scope of protection of the present invention.

[0023] In this invention, the technical features described in an open-ended manner include both closed-ended technical solutions composed of the listed features and open-ended technical solutions that include the listed features.

[0024] In this invention, numerical ranges are involved. Unless otherwise specified, the numerical ranges are considered continuous and include the minimum and maximum values ​​of the range, as well as every value between the minimum and maximum values. Furthermore, when the range refers to integers, it includes every integer between the minimum and maximum values ​​of the range. Additionally, when multiple ranges are provided to describe features or characteristics, the ranges may be merged. In other words, unless otherwise specified, all ranges disclosed herein should be understood to include any and all subranges to which they are included.

[0025] In this invention, there are no particular limitations on the specific dispersion and stirring methods.

[0026] Unless otherwise specified, all reagents or instruments used in this invention are commercially available conventional products. Unless otherwise specified, the raw materials used in each comparative example and the parallel experiments of each embodiment are the same commercially available products.

[0027] This application provides a flurana chewable tablet comprising the following components by weight percentage: 19-23% flurana complex, 6-10% palatability enhancer, 6-10% flavoring agent, 6-10% binder, 10-15% wetting agent, 3-6% disintegrant, 2-5% lubricant, and the balance being filler.

[0028] The fluranarine chewable tablets described in this application are based on fillers and fluranarine complexes. By adding palatability enhancers, flavoring agents, binders, wetting agents, disintegrants, and lubricants, and by rationally selecting and controlling the proportions of each excipient, the resulting fluranarine chewable tablets exhibit good stability, excellent in vitro dissolution performance, and can significantly improve the in vivo release effect of the drug, effectively improving the in vivo bioavailability of fluranarine.

[0029] The mass percentage of the freranil compound is 19-23%, for example, it can be 19%, 19.5%, 20%, 20.5%, 21.5%, 22%, 22.5%, 23% or any two of these values.

[0030] The palatability enhancer has a mass percentage of 6-10%, for example, it can be 6%, 6.5%, 7%, 7.5%, 8%, 8.5%, 9%, 9.5%, 10%, or any two of these values.

[0031] The flavoring agent has a mass percentage of 6-10%, for example, it can be 6%, 6.5%, 7%, 7.5%, 8%, 8.5%, 9%, 9.5%, 10% or any two of these values.

[0032] The adhesive has a mass percentage of 6 to 10%, for example, it can be 6%, 6.5%, 7%, 7.5%, 8%, 8.5%, 9%, 9.5%, 10% or any two of these values.

[0033] The wetting agent has a mass percentage of 10-15%, for example, it can be 10%, 10.5%, 11%, 11.5%, 12%, 12.5%, 13%, 13.5%, 14%, 14.5%, 15% or any two of these values.

[0034] The disintegrant has a mass percentage of 3 to 6%, for example, it can be 3%, 3.5%, 4%, 4.5%, 5%, 5.5%, 6% or any two of these values.

[0035] The lubricant has a mass percentage of 2-5%, for example, it can be 2%, 2.5%, 3%, 3.5%, 4%, 4.5%, 5% or any two of these values.

[0036] In some embodiments, the preparation method of the freranil complex is as follows: (1) Disperse fluorenazine in anhydrous ethanol to obtain fluorenazine solution; disperse sodium caseinate in water to obtain sodium caseinate solution; (2) Add sodium caseinate solution to freranilate solution, adjust pH to 8.8~9.2, stir for 20~40 min, then adjust pH to 7.5~7.8, stir for 30~50 min, then add vitamin E polyethylene glycol succinate and betaine, stir evenly to obtain a mixture; (3) The mixture was subjected to high-pressure microjet treatment, freeze-dried, and ground to obtain the Freranar complex.

[0037] This application describes the preparation of a fluranar complex with excellent stability, dispersibility, in vivo release effect, and in vivo bioavailability by first mixing fluranar and sodium caseinate in solution, adjusting the pH to 8.8-9.2, then adjusting the pH to 7.5-7.8, and adding vitamin E polyethylene glycol succinate and betaine.

[0038] The sodium caseinate possesses superior water solubility and molecular dispersibility, forming a uniform and flexible protein network in an aqueous system to comprehensively encapsulate and disperse hydrophobic flurana particles, effectively preventing drug particle aggregation. Trehalose in the system forms a dense and stable intermolecular hydrogen bond network with sodium caseinate and flurana molecules, effectively binding drug molecule movement and inhibiting flurana molecule rearrangement and crystal growth. Vitamin E polyethylene glycol succinate, as an amphiphilic functional modifier, effectively reduces the surface tension of the drug interface and improves the hydrophilicity of the flurana powder surface. Through the specific process of this application, the stability, in vivo release effect, and in vivo bioavailability of flurana can be significantly improved, enabling the chewable tablets to achieve stable and continuous drug release in vivo, with a uniform and controllable release rate, without significant burst release or delayed release phenomena. This enhances the drug's in vitro dissolution and gastrointestinal permeability, promoting rapid drug dissolution, efficient mucosal absorption, and rapid blood entry.

[0039] In some embodiments, the mass ratio of the fluranar to anhydrous ethanol is 1:(5~20).

[0040] In some embodiments, the mass ratio of sodium caseinate to water is 1:(5~20).

[0041] In some embodiments, the mass ratio of sodium caseinate solution, freranilate solution, vitamin E polyethylene glycol succinate, and betaine is (0.4~0.6):1, (0.01~0.02):(0.01~0.02).

[0042] In some embodiments, the pressure of the high-pressure microjet is 10,000 to 20,000 psi, and the treatment is performed 2 to 3 times.

[0043] In some embodiments, the filler is prepared by dispersing microcrystalline cellulose in water, adding pectin monoglyceride and octyl glucoside, stirring evenly to obtain a modified solution; adding calcium hydroxyphosphate and corn starch to the modified solution, stirring at 35~45°C for 20~60 min, freeze-drying, and grinding to obtain the filler.

[0044] This application utilizes a compound of microcrystalline cellulose, calcium hydroxyphosphate, and corn starch, and prepares a functionalized filler through modification with pectin monoglycerides and octyl glucoside, followed by freeze-drying. The modified filler possesses both hydrophilic groups and hydrophobic anchoring sites on its surface, allowing for excellent interfacial compatibility with supramolecularly modified fluranaran (sodium caseinate). This effectively improves powder mixing uniformity, inhibits drug particle aggregation and crystal rearrangement, and significantly enhances the storage stability of the formulation. Simultaneously, the modified filler optimizes the internal pore structure of the tablet, improves drug wetting and dissolution properties, promotes stable and uniform drug release in vivo, avoids significant fluctuations in blood drug concentration, and effectively reduces the risk of drug accumulation. Furthermore, the modified system enhances the gastrointestinal dissolution and penetration capacity of fluranaran, promoting efficient drug absorption into the bloodstream and significantly improving the bioavailability of the formulation.

[0045] In some embodiments, the mass ratio of microcrystalline cellulose, water, pectin monoglyceride, octyl glucoside, calcium hydroxyphosphate, and corn starch is (0.12~0.15):(5~20):(0.08~0.12):(0.05~0.08):(0.25~0.3):1.

[0046] In some embodiments, the palatability enhancer is at least one of chicken powder and pork liver powder.

[0047] In some embodiments, the flavoring agent is at least one of sucrose, sorbitol, maltitol, isomaltitol, and sucralose.

[0048] In some embodiments, the adhesive is polyethylene glycol 3350.

[0049] In some embodiments, the wetting agent is at least one of soybean oil and glycerin.

[0050] In some embodiments, the disintegrant is at least one of low-substituted hydroxypropyl cellulose and sodium carboxymethyl starch.

[0051] In some embodiments, the lubricant is magnesium stearate.

[0052] One embodiment of this application provides a method for preparing flurana chewable tablets, comprising the following steps: mixing flurana complex, palatability enhancer, flavoring agent, disintegrant, lubricant, and filler evenly, then adding binder and wetting agent, mixing evenly, and compressing into tablets to obtain flurana chewable tablets.

[0053] The present application is further illustrated below with specific embodiments:

[0054] Example 1 A flurana chewable tablet comprises the following components by weight percentage: 20% flurana complex, 7% chicken powder, 8% sucrose, 8% polyethylene glycol 3350, 12% wetting agent, 5% sodium carboxymethyl starch, 4% magnesium stearate, and the balance being filler.

[0055] The wetting agent is soybean oil and glycerin in a mass ratio of 1:1.

[0056] The preparation method of the freranil complex is as follows: (1) Disperse freranal in anhydrous ethanol to obtain freranal solution; disperse sodium caseinate in water to obtain sodium caseinate solution; the mass ratio of freranal to anhydrous ethanol is 1:9; the mass ratio of sodium caseinate to water is 1:9; (2) Add sodium caseinate solution to freranilate solution, adjust pH to 9 (adjusted with 1M sodium hydroxide solution), stir at 100 rpm for 30 min, then adjust pH to 7.6 (adjusted with 1M hydrochloric acid solution), stir at 100 rpm for 45 min, then add vitamin E polyethylene glycol succinate and betaine, stir at 100 rpm for 30 min to obtain a mixture; the mass ratio of sodium caseinate solution, freranilate solution, vitamin E polyethylene glycol succinate and betaine is 0.5:1 and 0.018:0.015.

[0057] (3) The mixture was subjected to high-pressure microjets, freeze-dried, and ground to 400 mesh to obtain the freranil complex. The pressure of the high-pressure microjets was 16,000 psi, and the treatment was performed 3 times.

[0058] The filler was prepared as follows: microcrystalline cellulose was dispersed in water, pectin monoglyceride and octyl glucoside were added, and the mixture was stirred at 100 rpm for 20 min to obtain a modified solution; calcium hydroxyphosphate and corn starch were added to the modified solution, and the mixture was stirred at 100 rpm for 50 min at 40°C, freeze-dried, and ground to 400 mesh to obtain the filler. The mass ratio of microcrystalline cellulose, water, pectin monoglyceride, octyl glucoside, calcium hydroxyphosphate, and corn starch was 0.14:10:0.1:0.06:0.28:1.

[0059] The preparation method of the flurana chewable tablets includes the following steps: mixing flurana complex, chicken powder, sucrose, sodium carboxymethyl starch, magnesium stearate and filler evenly, then adding polyethylene glycol 3350 and wetting agent, mixing evenly, and compressing into tablets to obtain flurana chewable tablets.

[0060] Example 2 The difference between Example 2 and Example 1 is that the amount of each raw material is different, but everything else is the same.

[0061] A flurana chewable tablet comprising the following components by weight percentage: 19% flurana complex, 10% chicken powder, 6% sucrose, 10% polyethylene glycol 3350, 10% wetting agent, 6% sodium carboxymethyl starch, 2% magnesium stearate, and the balance being filler.

[0062] Example 3 The difference between Example 3 and Example 1 is that the amount of each raw material is different, but everything else is the same.

[0063] A flurana chewable tablet comprising the following components by weight percentage: 23% flurana complex, 6% chicken powder, 10% sucrose, 6% polyethylene glycol 3350, 15% wetting agent, 3% sodium carboxymethyl starch, 5% magnesium stearate, and the balance being filler.

[0064] Comparative Example 1 The difference between Comparative Example 1 and Example 1 is that an equal amount of freranal was used to replace the freranal compound, while everything else is the same.

[0065] A flurana chewable tablet comprises the following components by weight percentage: 15% flurana, 7% chicken powder, 8% sucrose, 8% polyethylene glycol 3350, 12% wetting agent, 5% sodium carboxymethyl starch, 4% magnesium stearate, and the balance being filler.

[0066] Comparative Example 2 The difference between Comparative Example 2 and Example 1 is that the preparation method of the freranil complex is different, but everything else is the same.

[0067] The preparation method of the fluorellarano compound in this comparative example is as follows: (1) Disperse freranal in anhydrous ethanol to obtain freranal solution; disperse sodium caseinate in water to obtain sodium caseinate solution; the mass ratio of freranal to anhydrous ethanol is 1:9; the mass ratio of sodium caseinate to water is 1:9; (2) Add sodium caseinate solution to freranilate solution, adjust pH to 9, stir at 100 rpm for 30 min, then adjust pH to 7.6, stir at 100 rpm for 45 min to obtain a mixture; the mass ratio of sodium caseinate solution to freranilate solution is 0.5:1.

[0068] (3) The mixture was subjected to high-pressure microjets, freeze-dried, and ground to 400 mesh to obtain the freranil complex. The pressure of the high-pressure microjets was 16,000 psi, and the treatment was performed 3 times.

[0069] Comparative Example 3 The difference between Comparative Example 3 and Example 1 is that the preparation method of the freranil complex is different, but everything else is the same.

[0070] The preparation method of the fluorellarano compound in this comparative example is as follows: (1) Disperse freranal in anhydrous ethanol to obtain freranal solution; disperse sodium caseinate in water to obtain sodium caseinate solution; the mass ratio of freranal to anhydrous ethanol is 1:9; the mass ratio of sodium caseinate to water is 1:9; (2) Add vitamin E polyethylene glycol succinate and betaine to the Freranar solution and stir at 100 rpm for 45 min to obtain a mixture; the mass ratio of Freranar solution, vitamin E polyethylene glycol succinate and betaine is 1, 0.018: 0.015.

[0071] (3) The mixture was subjected to high-pressure microjets, freeze-dried, and ground to 400 mesh to obtain the freranil complex. The pressure of the high-pressure microjets was 16,000 psi, and the treatment was performed 3 times.

[0072] Comparative Example 4 The difference between Comparative Example 4 and Example 1 is that the filler in Comparative Example 4 is an equal amount of corn starch, while everything else is the same.

[0073] A flurana chewable tablet comprising the following components by weight percentage: 20% flurana complex, 7% chicken powder, 8% sucrose, 8% polyethylene glycol 3350, 12% wetting agent, 5% sodium carboxymethyl starch, 4% magnesium stearate, and the balance corn starch.

[0074] Comparative Example 5 The difference between Comparative Example 5 and Example 1 is that the preparation method of the filler in Comparative Example 5 is different from that in Example 1, but everything else is the same.

[0075] The filler in this comparative example was prepared as follows: microcrystalline cellulose was dispersed in water to obtain a modified solution; corn starch was added to the modified solution, stirred at 100 rpm for 50 min at 40°C, freeze-dried, and ground to 400 mesh to obtain the filler. The mass ratio of microcrystalline cellulose, water, and corn starch was 0.14:0.28:1.

[0076] Test case 1. Stability: Chewable tablet samples were placed at 40°C / 75%RH±5% for 6 months. The changes in content were measured and the appearance was observed. The retention rate of fluranar was recorded. Fluranar retention rate = fluranar content after 6 months / initial fluranar content.

[0077] Table 1

[0078] 2. Dissolution effect: CTAB (hexadecyltrimethylammonium bromide) was added to PBS buffer at a concentration of 1 wt%. Chewable tablet samples were added to the solution. At 37.5°C, 1 mL of dissolution solution was taken out at 5, 10, 15, 30, 60 and 120 min respectively, and the same volume of dissolution medium was added at the same temperature. The solution was filtered through a 0.22 μm filter membrane to test its dissolution rate.

[0079] 3. In vivo pharmacokinetic study: Twenty-four healthy male SD rats were randomly divided into eight groups of three. After one week of acclimatization, their body weight was 250g ± 10g. Before administration, rats were fasted for 12 hours but allowed free access to water. Fluranaridine soft chewable tablets were administered by gavage at a dose of 80mg / kg. Rats were fed one hour after administration. Blood samples of 0.4mL were collected from the jugular venous plexus at time points: before administration, and at 1h, 2h, 4h, 8h, 16h, 24h, 28h, 30h, 32h, 34h, 36h, 38h, 40h, and 48h after administration. These samples were added to centrifuge tubes containing 10μL of EDTA anticoagulant, mixed thoroughly, and the maximum plasma concentration of fluranaridine and the time to reach that concentration were measured in the rats.

[0080] Table 2

[0081] As can be seen from Tables 1-2, the fluranar sodium described in this application has excellent stability, dissolution rate and bioavailability.

[0082] Finally, it should be noted that the above embodiments are used to illustrate the technical solutions of the present invention and not to limit the scope of protection of the present invention. Although the present invention has been described in detail with reference to preferred embodiments, those skilled in the art should understand that modifications or equivalent substitutions can be made to the technical solutions of the present invention without departing from the essence and scope of the technical solutions of the present invention.

Claims

1. A fluranarol chewable tablet, characterized in that, It includes the following components by weight percentage: 19-23% Freranar compound, 6-10% palatability enhancer, 6-10% flavoring agent, 6-10% binder, 10-15% wetting agent, 3-6% disintegrant, 2-5% lubricant, and balance filler.

2. The fluranarol chewable tablet according to claim 1, characterized in that, The preparation method of the fluorellarano compound is as follows: (1) Disperse fluorenazine in anhydrous ethanol to obtain fluorenazine solution; disperse sodium caseinate in water to obtain sodium caseinate solution; (2) Add sodium caseinate solution to freranilate solution, adjust pH to 8.8~9.2, stir for 20~40 min, then adjust pH to 7.5~7.8, stir for 30~50 min, then add vitamin E polyethylene glycol succinate and betaine, stir evenly to obtain a mixture; (3) The mixture was subjected to high-pressure microjet treatment, freeze-dried, and ground to obtain the Freranar complex.

3. The fluranarol chewable tablet according to claim 2, characterized in that, The mass ratio of the fluranar and anhydrous ethanol is 1:(5~20). The mass ratio of sodium caseinate to water is 1:(5~20).

4. The fluranarol chewable tablet according to claim 2, characterized in that, The mass ratio of sodium caseinate solution, freranilate solution, vitamin E polyethylene glycol succinate, and betaine is (0.4~0.6):1, (0.01~0.02):(0.01~0.02).

5. The fluranarol chewable tablet according to claim 2, characterized in that, The pressure of the high-pressure microjet is 10,000~20,000 psi, and the treatment is performed 2~3 times.

6. The fluranarol chewable tablet according to claim 1, characterized in that, The filler is prepared by dispersing microcrystalline cellulose in water, adding pectin monoglyceride and octyl glucoside, stirring evenly to obtain a modified solution; adding calcium hydroxyphosphate and corn starch to the modified solution, stirring at 35~45°C for 20~60 min, freeze-drying, and grinding to obtain the filler.

7. The fluranarol chewable tablet according to claim 6, characterized in that, The mass ratio of microcrystalline cellulose, water, pectin monoglyceride, octyl glucoside, hydroxycalcium phosphate, and corn starch is (0.12~0.15):(5~20):(0.08~0.12):(0.05~0.08):(0.25~0.3):

1.

8. The fluranarol chewable tablet according to claim 1, characterized in that, The palatability enhancer is at least one of chicken powder and pork liver powder; The flavoring agent is at least one of sucrose, sorbitol, maltitol, isomaltitol, and sucralose. The adhesive is polyethylene glycol 3350.

9. The fluranarol chewable tablet according to claim 1, characterized in that, The wetting agent is at least one of soybean oil and glycerin; The disintegrant is at least one of low-substituted hydroxypropyl cellulose and sodium carboxymethyl starch; The lubricant is magnesium stearate.

10. A method for preparing fluranarol chewable tablets according to any one of claims 1 to 9, characterized in that, Includes the following steps: The flurana complex, palatability enhancer, flavoring agent, disintegrant, lubricant, and filler are mixed evenly, and then the binder and wetting agent are added, mixed evenly, and compressed into tablets to obtain flurana chewable tablets.

Images